• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
PainReform Ltd. (PRFX) Stock Price, News & Analysis

PainReform Ltd. (PRFX) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.94

-$0.26

(-8.13%)

Day's range
$2.51
Day's range
$3.14
50-day range
$1.73
Day's range
$7.28
  • Country: IL
  • ISIN: IL0011651580
52 wk range
$0.43
Day's range
$20.16


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -44.10
  • Piotroski Score 2.00
  • Grade Hold
  • Symbol (PRFX)
  • Company PainReform Ltd.
  • Price $2.94
  • Changes Percentage (-8.13%)
  • Change -$0.26
  • Day Low $2.51
  • Day High $3.14
  • Year High $20.16

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/25/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$7.74
  • Trailing P/E Ratio -0.08
  • Forward P/E Ratio -0.08
  • P/E Growth -0.08
  • Net Income $-9,344,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

PainReform Ltd. Frequently Asked Questions

  • What were the earnings of PRFX in the last quarter?

    In the last quarter PainReform Ltd. earnings were on Thursday, August, 15th. The PainReform Ltd. maker reported -$2.40 EPS for the quarter, beating analysts' consensus estimates of -$6.24 by $3.84.

  • What is the PainReform Ltd. stock price today?

    Today's price of PainReform Ltd. is $2.94 — it has decreased by -8.13% in the past 24 hours. Watch PainReform Ltd. stock price performance more closely on the chart.

  • Does PainReform Ltd. release reports?

    Yes, you can track PainReform Ltd.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the PainReform Ltd. stock forecast?

    Watch the PainReform Ltd. chart and read a more detailed PainReform Ltd. stock forecast to see what analysts suggest you do with its shares.

  • What is PainReform Ltd. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by PainReform Ltd. stock ticker.

  • How to buy PainReform Ltd. stocks?

    Like other stocks, PRFX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is PainReform Ltd.'s EBITDA?

    PainReform Ltd. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in PainReform Ltd.’s financial statements.

  • What is the PainReform Ltd.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in PainReform Ltd. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including PainReform Ltd.'s financials relevant news, and technical analysis. PainReform Ltd.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for PainReform Ltd. stock currently indicates a “sell” signal. For more insights, review PainReform Ltd.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.